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Surface-exposed Toll-like receptors (TLRs) such 
as TLR2 and TLR4 survey the extracellular 
environment for pathogens. TLR activation 
initiates the production of various cytokines and 
chemokines including type I interferons (IFN-I). 
Downstream of TLR4, IFNβ secretion is only 
vigorously triggered in macrophages when the 
receptor undergoes endocytosis and switches 
signaling adaptor; surface TLR4 engagement 
predominantly induces proinflammatory cytokines 
via the signaling adaptor MyD88. It is unclear if 
this dichotomy is generally applicable to other 
TLRs, cell types, or differentiation states.
Here, we report that diverse TLR2 ligands induce 
an IFN-I response in human monocyte-like cells, 
but not in differentiated macrophages. This TLR2-
dependent IFN-I signaling originates from the cell 
surface and is dependent on MyD88; it involves 
combined activation of the transcription factors 
IRF3 and NF-κB, driven by the kinases TBK1 and 
TAK1-IKKβ, respectively. TLR2-stimulated 
monocytes produced modest IFNβ levels that 
caused productive downstream signaling, reflected 
by STAT1-phosphorylation and expression of 
numerous interferon-stimulated genes (ISGs). Our 
findings reveal that the outcome of TLR2 signaling 
includes an IFN-I response in human monocytes, 
which is lost upon macrophage differentiation, and 
differs mechanistically from IFN-I-induction 
through TLR4. These findings point to molecular
mechanisms tailored to the differentiation state of 
a cell and the nature of receptors activated to 
control and limit TLR-triggered IFN-I responses.
Introduction
A crucial step for activation of innate immunity is 
detection of invading pathogens. Cells sense 
microbes through a set of pattern recognition 
receptors (PRRs) that recognize conserved 
microbial structures, known as pathogen-
associated molecular patterns (PAMPs) (1). TLRs 
constitute a family of transmembrane PRRs well-
known for inducing innate defense against a 
plethora of microbes (2,3). Upon ligand binding, 
TLRs initiate signaling events that result in the 
production of a large variety of cytokines, 
chemokines, and co-stimulatory molecules, which 
activate and polarize innate and adaptive immune 
cells (4,5). A properly tailored innate immune 
response results in the clearance of pathogens, 
while minimizing inflammation-associated 
damage to the host. Whereas the molecular aspects 
of TLR sensing and signaling have been resolved 
to great detail in specific cell types, knowledge lags 
behind on how immune responses of appropriate 
quality (specificity, amplitude, and duration) are 
induced at the levels of cells, tissues, and 
organisms. 
Among the TLR-induced cytokines, IFN-I, such as 
IFNα and IFNβ, mediate particularly potent 
antimicrobial effects. Secreted IFN-I can bind the 
IFN-α/β receptor (IFNAR) in an autocrine or 
paracrine manner to induce the expression of 
hundreds of ISGs (6). Many ISGs directly inhibit 
replication of intracellular microbes (7-9). In vivo
studies illustrate the power of IFN-I in anti-viral 
immunity, showing that administration of 
exogenous IFN-I protects mice from a lethal 
challenge of mouse adapted human Influenza virus 
(10) and that IFNAR1-deficient mice are extremely 
susceptible to numerous viruses, such as vesicular 
stomatitis virus (VSV), vaccinia virus, Semliki 
forest virus, and lymphocytic choriomeningitis 
virus (LCMV) (11). Similarly, IFN-I play an 
important role in the innate defense against various 
bacteria. For instance, IFNAR-deficient mice 
succumb when infected with group B streptococci 
(GBS), Escherichia coli, or Streptococcus 
pyogenes (12,13), whereas wild-type mice survive 
these infections. 
A potent effector function of IFN-I is to suppress 
cell proliferation and sensitize cells to apoptosis 
(14,15). While providing an effective way to clear 
infected cells, this can also have detrimental 
effects. For instance, IFN-I-related apoptosis of 
macrophages and T cells increases host 
susceptibility to Listeria monocytogenes (9).
Adverse effects of prolonged production of high 
levels of IFN-I also manifest in patients suffering 
from interferonopathies, a group of 
autoinflammatory disorders where uncontrolled 























Thus, IFN-I responses following TLR activation 
should be tightly regulated to induce optimal anti-
microbial effects, yet limit immunopathology.
IFN-I production following TLR activation differs 
vastly among cell types. For instance, subsets of 
dendritic cells (DCs) display extensive variation in 
TLR7- and TLR9-induced IFN-I levels. 
Intracellular TLR7 and TLR9 molecules survey 
endosomes for the presence of viral single-stranded 
RNA (17) and unmethylated DNA containing CpG 
motifs (18), respectively. In plasmacytoid DCs 
(pDCs), ligation of TLR7 or TLR9 results in the 
secretion of large quantities of IFN-I, while 
signaling via these receptors in conventional DCs 
(cDCs) induces much less IFN-I and, instead, 
mainly triggers the production of proinflammatory 
cytokines (19,20). Although not completely 
resolved, the two DC subsets appear to trigger IFN-
I production through distinct TLR7/9-induced 
molecular mechanisms (21). To understand the 
variation in the outcome of TLR ligation, it is, 
therefore, important to dissect the signaling 
cascades that culminate in the production of IFN-I
for individual cell types. 
Some surface expressed TLRs yield 
proinflammatory as well as IFN-I responses within 
one cell type. The molecular basis for IFN-I
synthesis has been most thoroughly dissected for 
TLR4 signaling in mouse macrophages, with many 
aspects being confirmed in human macrophages 
(22-24). Here, signaling events underpinning the 
synthesis of either IFN-I or the proinflammatory 
cytokines appear to be spatially separated (25).
Engagement of TLR4 with bacterial 
lipopolysaccharides (LPS) at the cell surface 
induces receptor dimerization, leading to the 
recruitment of sorting and signaling adaptors TIR 
domain-containing adaptor protein (TIRAP, also 
termed Mal) and myeloid differentiation primary 
response 88 (MyD88) (26). Downstream MyD88, 
signaling involves transforming growth factor-β-
activated kinase-1 (TAK1), resulting in the nuclear 
translocation of the transcription factors nuclear 
factor-κB (NF-κB) and activator protein-1 (AP-1) 
(27). Jointly, NF-κB and AP-1 drive the expression 
of proinflammatory cytokines, such as interleukin-
8 (IL8) and tumor necrosis factor-α (TNFα), but 
not of IFN-I. The switch to IFN-I production 
occurs following endocytosis of LPS-engaged 
TLR4 dimers. From endosomes, TLR4 engages a 
different set of sorting and signaling adaptor 
proteins, namely TRIF-related adaptor molecule 
(TRAM) and TIR domain-containing adaptor 
inducing IFNβ (TRIF) (28,29). These interactions 
promote signaling via TANK-binding kinase 1 
(TBK1) and IκB kinase ε (IKKε), driving the 
phosphorylation of IFN regulatory factor 3 (IRF3) 
(30). The transcription factor IRF3 then dimerizes 
and translocates to the nucleus to induce the 
expression of vast amounts of IFNβ (31). Thus, 
macrophages appear to have evolved complex 
mechanisms to regulate the TLR4-dependent 
induction of IFN-I, with cellular trafficking events 
tailoring signaling outcome. 
TLR2 is the second surface-exposed TLR that, 
although long thought to only induce 
proinflammatory cytokines, also leads to IFN-I
production in mouse monocytes and macrophages 
(32,33). TLR2 heterodimerizes with TLR1 or 
TLR6 to allow detection of a broad spectrum of 
PAMPs including glycolipids, lipoproteins (34),
and various virus structural proteins (35,36).
Mechanistic details for TLR2 have not been 
resolved to the same detail as for TLR4. IFN-I
induction downstream of murine TLR2 differs 
from TLR4 in that all TLR2-signaling events 
require the adaptor MyD88 (32,33). Yet, analogous 
to TLR4, endocytosis of murine TLR2 molecules 
appears to drive activation of IRF transcription 
factors (37). It is even less clear how IFN-I is 
induced downstream of human TLR2 and in which 
cells. 
In this study, we found that human TLR2 signaling 
outcome differs between monocytes and 
macrophages - by comparing these two 
differentiation states of THP1 myeloid cells - and
elucidated how human TLR2 signals leading to 
IFN-I production are transduced. This work 
deepens our understanding of the strategies that 
cells employ to regulate their IFN-I output and 
what roles receptor usage and cellular 
differentiation play.
Results
Human monocytes, but not macrophages, 























To investigate TLR2 signaling in human myeloid 
cells, we employed the human acute monocytic 
leukemia-derived cell line THP1, which is highly 
manipulable and widely used for deciphering 
mechanistic aspects of (innate) immune signaling 
(38,39). THP1 cells have a monocyte-like 
phenotype and can be differentiated towards 
macrophage-like cells using the phorbol ester PMA 
(40). For ease of reading, we here refer to the 
undifferentiated and differentiated THP1 cells as 
monocytes and macrophages, respectively. Both 
THP1 monocytes and macrophages endogenously 
express TLR2, TLR1, and TLR6 (Supporting Fig. 
1), permitting the study of TLR2 signaling in either 
differentiation state. 
First, we assessed which signaling pathways are 
activated upon TLR2 ligation in monocytes and 
macrophages using THP1 Dual reporter cells. 
These cells secrete inducible reporter proteins 
reflecting activation of the IRF (Lucia luciferase) 
and NF-κB (secreted embryonic alkaline 
phosphatase, SEAP) pathways. Monocytes and 
macrophages were incubated for 24hr with the 
TLR2 ligand Pam2CSK4 (P2C), IFNα as a positive 
control for inducing IRF activity, or TNFα as a 
positive control for inducing NF-κB activity. P2C-
stimulated monocytes induced the IRF-reporter 10-
fold over unstimulated cells (Fig. 1A, left panel), 
indicating that IRF activity was induced by TLR2. 
To our surprise, this response was lost in 
differentiated cells. In contrast, high levels of 
SEAP were detected in the supernatants of both 
P2C-stimulated monocytes and macrophages (Fig. 
1A, right panel), pointing to robust TLR2-induced 
NF-κB activation, irrespective of the 
differentiation state of the cells. For comparison, 
LPS stimulation showed that TLR4 engagement 
resulted in IRF signaling in addition to NF-κB 
signaling in macrophages (Fig. 1A), as reported by 
others (29,41). Thus, human monocytes display 
TLR2-induced NF-κB and IRF activity, the latter 
of which is lost in differentiated cells. 
Second, we analyzed if TLR2 signaling in 
monocytes led to the production of both IFN-I and 
proinflammatory cytokines, as implicated by the 
reporter assay results above. Quantitative real-time 
PCR (qRT-PCR) analysis revealed rapid and 
transient IFNβ transcription in P2C-stimulated 
monocytes, but not macrophages (Fig. 1B), with a 
peak 1hr after stimulation (Fig. 1C). The transient 
burst of IFNβ expression in monocytes was 
followed by sustained expression of various ISGs, 
including CXCL10, ISG15, ISG54, IRF7, and 
Viperin (Fig. 1B,C), which is indicative of 
productive IFN-I signaling. Note that all ISGs were 
expressed by monocytes 4hrs after stimulation 
(Fig. 1B), but that each reached maximum 
expression at different times after TLR2 activation 
(Fig. 1C). In contrast to the monocyte-restricted 
expression of IFNβ and ISGs, both P2C-stimulated 
monocytes and macrophages upregulated the NF-
κB-inducible TNFα, IL8, and CCL5 mRNAs (Fig. 
1B), confirming the NF-κB-SEAP reporter data 
(Fig. 1A). Secreted IFNβ protein levels in culture 
supernatants were below 10 IU/ml, the detection 
limit of the HEK Blue IFNαβ reporter assay (data 
not shown). As a proxy of IFN-I signaling at the 
protein level, we measured upregulation of ISG15 
in permeabilized cells by flow cytometry. ISG15 is 
an IFN-I-inducible ubiquitin-like protein, which 
serves as a post-translational modifier of proteins 
through covalent attachment. The large majority of 
P2C-stimulated monocytes became strongly 
ISG15-positive (Fig. 1D,E), confirming the qRT-
PCR results (Fig. 1B,C). ISG15 can act as an IFN-
I-independent direct response gene (42). In these 
experiments, however, TLR2-mediated ISG15 
induction was entirely dependent on IFN-I
signaling, as P2C no longer induced ISG15 in 
monocytes lacking the IFNAR2 receptor (Fig. 
1D,E; nor did two other TLR2 ligands, P3C and 
FSL-1 (Supporting Fig. 2A).
The combined results - from reporter assays, qRT-
PCRs, and flow cytometry - thus demonstrate that 
the TLR2-induced IFNβ levels were sufficient to 
drive a productive IFN-I response in the 
monocytes. In conclusion, while both monocytes 
and macrophages induce NF-κB-dependent gene 
expression following TLR2 stimulation, the 
induction of IFNβ and subsequent IFN-I signaling 
is restricted to human monocytes.
Ligands for TLR1/2 and 2/6 heterodimers both
induce dose-dependent IFN-I signaling in 
human monocytes
Heterodimerization of TLR2 with either TLR1 or 
TLR6 yields variable binding affinities for diverse 























preferentially binds to TLR2/1 complexes (44),
whereas FSL-1 is considered a TLR2/6 ligand (43).
Both P3C and FSL-1 triggered IRF activity in 
monocytes in a dose-dependent fashion, like P2C
did (Fig. 2A). Although we observed some 
variation among the ligands as well as between 
replicate experiments, there was a tendency that 
higher ligand doses might be required for 
activation of the IRF than the NF-κB pathway (Fig. 
2A and data not shown: roughly 2- to 5-fold more 
for the IRF reporter than for the NF-κB reporter). 
Macrophages did not yield an IRF response to any 
of these ligands, even at high doses (Fig. 2B). This 
differentiation state-dependent difference was 
confirmed at the protein level, as only monocytes 
upregulated ISG15 in response to the diverse TLR2 
ligands (Fig. 2C,D (P2C, P3C) and Supporting Fig. 
2B (FSL-1)), while both monocytes and 
macrophages were responsive to control treatment 
with IFNα (virtually 100% ISG15-positive cells).
In summary, upon ligand engagement, both 
TLR2/1 and TLR2/6 receptor heterodimers appear 
to evoke an IFN-I response in human monocytes.
MyD88 is essential for TLR2-induced IFN-I
signaling in human monocytes, unlike for TLR4 
in macrophages
Next, we aimed to determine the requirements for 
the IFN-I response downstream of human TLR2. 
TLRs relay distinct signaling outcomes through the 
use of various signaling adaptors. TLR4 employs 
MyD88 to confer NF-κB activation, whereas IRF 
activity is induced via TRIF (28). However, 
experiments suggest that this dichotomy does not 
apply for mouse TLR2, as MyD88 expression was 
essential for the activation of NF-κB, but also for 
the induction of IFN-I (32,33). To determine the 
role MyD88 plays in the TLR2-dependent IFN-I
response in human monocytes, we examined THP1 
cells devoid of MyD88 expression (ΔMyD88 
cells). 
In response to P2C, P3C, or FSL-1 stimulation, 
ΔMyD88 monocytes completely lost the ability to 
upregulate intracellular ISG15 protein levels (Fig. 
3A,B, left panels; Supporting Fig. 2C) and did not 
produce IFNβ or ISG54 transcripts (Fig. 3C). From 
this, we conclude that MyD88 is an absolute 
requirement downstream of human TLR2 to confer 
the signaling events leading to IFN-I, reminiscent 
of observations in mouse cells. In contrast, 
ΔMyD88 macrophages retained induction of 
ISG15, IFNβ, and ISG54 when exposed to the 
TLR4 ligand LPS (Fig. 3A,B, right panels, and D), 
although the response was less pronounced than in 
wild-type cells. These combined data reveal that, 
whereas MyD88-independent TLR4 signaling in 
macrophages still results in an IFN-I response, no 
IFN-I is induced upon TLR2 ligation when the 
adaptor MyD88 is absent from human monocytes. 
TLR2 induces IFN-I production in human 
monocytes via the signaling intermediates 
TBK1 and IRF3
To obtain insight into how monocytes regulate 
IFNβ expression following TLR2 stimulation, we 
dissected the underlying MyD88-dependent 
signaling pathway. Various PRRs initiate 
expression of IFNβ by activating members of the 
IRF transcription factor family (45). In case of 
TLR4 signaling, a set of non-canonical IKKs, 
TBK1 and IKKε, drive the activation of IRF3 to 
induce IFNβ transcription (30). MyD88-dependent 
activation of TBK1 and IKKε occurs in murine 
bone marrow derived macrophages (BMDMs) 
stimulated with TLR2 ligands (46). Hence, we 
explored the role of TBK1 and IRFs in TLR2-
mediated IFN-I induction and subsequent IFNAR 
signaling by human monocytes (Fig. 4A).
First, Western blot analysis was employed to
visualize phosphorylation of TBK1, IRF3, and 
signal transducer and activator of transcription-1
(STAT1) in monocytes that were stimulated for 
various times with the TLR2 ligand P2C. As a 
positive control, lysates of macrophages stimulated 
with the TLR4 ligand LPS were taken along. Rapid 
phosphorylation of TBK1 at Ser172 was observed 
in P2C-stimulated monocytes and in LPS-
stimulated macrophages (Fig. 4B), pointing to 
activation of this kinase through 
(auto)phosphorylation (47). This was followed by 
robust phosphorylation of IRF3 at Ser396 in LPS-
stimulated macrophages, yet - unexpectedly - not 
detectably in P2C-stimulated monocytes. Still, in 
both cases, the transcription factor STAT1 was 
subsequently activated, as phospho-STAT1 bands 
appeared at later time points (Fig. 4B), indicative 
of a secondary IFN-I signaling cascade 























phosphorylation levels (Fig. 4B) mirrored the 
observed IFNβ mRNA levels (Fig. 3C,D), since 
both were more modest in P2C-stimulated 
monocytes than in LPS-stimulated macrophages. 
The kinase activity of TBK1 was required for 
inducing IFN-I downstream of TLR2: in response 
to P2C, monocytes pre-treated with the 
TBK1/IKKε inhibitor MRT67307 (48) induced 
significantly less IFNβ and ISG54 mRNA, whereas 
elevated levels of the NF-κB-regulated gene IL8 
were detected (Fig. 4C). This was in line with 
observations by others for a different TLR2 ligand, 
lipoteichoic acid (LTA) (49). In addition, 
MRT67307 dose dependently inhibited TLR2-, but 
not IFNα-, induced ISG15 protein expression (Fig. 
4D,E), confirming the involvement of TBK1/IKKε 
kinase activity in productive IFN-I signaling 
downstream of human TLR2.
In view of the contributions of upstream TBK1 
(Fig. 4B-E) and downstream STAT1 (Fig. 4B), we 
were surprised that IRF3 phosphorylation was not 
detected in our experimental set-up (Fig. 4B). 
Examples have been reported where the role of 
IRF3 only became evident from depletion 
experiments, potentially related to (in)sensitivity 
of the IRF3 activation assays used. For instance, 
siRNA experiments in human fibroblasts showed 
that IRF3 was required for the induction of ISGs in 
response to UV-inactivated Newcastle Disease 
Virus (NDV) and Human Cytomegalovirus 
(HCMV), despite a lack of detectable levels of 
IRF3 dimerization or Ser396 phosphorylation (50).
To conclusively determine whether IRF3 is 
involved in TLR2-induced IFN-I signaling in 
human monocytes, we made use of IRF3 knockout 
THP1 Dual cells (ΔIRF3). Incubation with the 
TLR2 ligands P2C, P3C (TLR2/1), or FSL-1
(TLR2/6) yielded only marginal IRF reporter 
activity in ΔIRF3 monocytes, as opposed to the 9-
to 14-fold increase in their wild-type counterparts 
(Fig. 4F, left panel). As a control, ΔIRF3 cells 
robustly induced the IRF-Lucia reporter following 
exposure to IFNα, indicating that IFNAR signaling 
was not disrupted in these cells. The TLR2 ligands 
triggered strong NF-κB activity both in wild-type
and ΔIRF3 cells, implying that IRF3 has no major 
effect on NF-κB activation (Fig. 4F, right panel). 
In line with the IRF reporter data, ΔIRF3 cells were 
also hampered in ISG15 protein induction in 
response to diverse TLR2 ligands (P2C, P3C, FSL-
1), while the response to IFNα treatment remained 
intact (Fig. 4G). This substantiates that the major 
IRF driving TLR1/2- and 2/6-induced IFN-I
signaling in human monocytes is IRF3. 
Since a weak TLR2-induced IRF activity remained 
detectable upon genetic depletion of IRF3 (2- to 4-
fold; Fig. 4F, left panel), other IRF family 
members may play an additional - minor - role. In 
addition to IRF3, monocytes express the myeloid-
specific IRF8 and the IFN-I-inducible IRF7 
transcription factors, of which the latter was only 
detectable in Western blots of IFN-I-treated cells 
(data not shown). To assess the contribution of 
these IRFs to TLR2-dependent IFN-I signaling, 
expression of IRF7 and IRF8 was silenced in THP1 
monocytes (Supporting Fig. 3A,B). Without 
affecting IRF3 protein levels (Supporting Fig. 3B), 
knockdown of IRF7 or IRF8 reduced - but did not 
completely abolish - TLR2-induced ISG15 
expression (Supporting Fig. 3C). Therefore, both 
IRF7 and IRF8 may contribute to the TLR2-
induced IFN-I response in human monocytes.
Combined, our findings support a model for human 
monocytes wherein TLR2 depends on TBK1 to 
modestly activate IRF3 which, together with other 
IRF family members, drives the expression of 
IFNβ (Fig. 4A).
Downstream of TAK1, the NF-κB, but not AP-
1, signaling axis contributes to TLR2-dependent 
IFN-I induction in human monocytes
Besides IRF-family members, the transcription 
factors NF-κB and AP-1 (ATF2/cJun) are activated 
upon TLR2 stimulation (Fig. 1A, right panel and 
(51)). Since both NF-κB and AP-1 can also bind 
and regulate the IFNβ promoter (52), one could 
envisage that signaling modules driving these 
transcription factors contribute to TLR2-dependent 
induction of IFNβ in human monocytes in 
conjunction with the TBK1/IRF3 axis, particularly 
when IRF3 is modestly activated. To test this, we 
performed experiments using inhibitors targeting
kinases that act in the NF-κB or AP-1 signaling 
pathways downstream TLR2 (Fig. 5A).
TAK1 forms a central signaling hub in the 























activation of both NF-κB and AP-1 (27).  A role 
for this kinase in regulating secretion of IFN-I
besides TNFα was implicated in LTA- or S.
aureus-treated cells based on the use of a broadly 
acting kinase inhibitor, 5Z-7-Oxozeaenol (49). We 
confirmed the role of TAK1 in human TLR2 
signaling as follows: pre-treatment of THP1 
monocytes with the recently published, highly 
specific inhibitor of TAK1 Takinib (53) virtually 
abolished P2C-induced expression of the NF-κB-
regulated gene product IL8 and significantly 
reduced TLR2-dependent expression of IFNβ and 
ISG54 mRNAs (Fig. 5B). At the highest dose 
tested, Takinib treatment almost completely 
blocked ISG15 production (Fig. 5D,E). At the 
same time, IFNα-induced ISG15 levels were not 
affected, excluding broadly toxic effects of the 
inhibitor at the concentrations used. Thus, TAK1 
activity is required for TLR2-dependent synthesis 
of IFNβ to levels that support productive IFN-I
signaling.
Downstream of TAK1, signaling diverges and 
either cascade may effectuate the observed role of 
TAK1 in IFN-I induction (Fig. 5A). On the one 
hand, TAK1 recruits and activates an IκB kinase 
complex, consisting of IKKα, IKKβ, and IKKγ, 
that ultimately leads to activation and nuclear 
translocation of NF-κB. On the other hand, TAK1 
triggers several mitogen-activated protein kinase 
(MAPK) pathways that drive AP-1 activation. We 
did not find alterations in TLR2-induced ISG15 
protein levels in THP1 monocytes pretreated with 
inhibitors of various MAPKs (Jun N-terminal 
kinases 1 and 2 (JNK1/2), MAPK/ERK kinases 1 
and 2 (MEK1/2), and p38α; Supporting Fig. 4). 
IFN-I induction in monocytes, therefore, does not 
appear to rely on the activation of AP-1. In 
contrast, in line with recent observations for other
TLR2 ligands (49), the inhibitor BI605906, which 
interferes with IKKβ activity and thereby 
selectively blocks NF-κB activation (48),
recapitulated the phenotypic effects of the TAK1 
inhibitor: in response to P2C, inhibitor-treated cells 
expressed significantly lower levels of IFNβ, 
ISG54, and IL8 transcripts (Fig. 5C) and displayed 
a dose-dependent reduction in induced ISG15 
levels (Fig. 5F,G). 
From these findings, we conclude that TAK1-
induced activation of NF-κB through IKKβ, rather 
than activation of AP-1 through MAPKs, is 
required - in conjunction with the TBK1/IRF3 
signaling axis - to optimally induce IFNβ 
expression and subsequent IFN-I signaling in 
human monocyte-like cells following TLR2 
stimulation.
TLR2 ligand engagement at the cell surface of 
human monocytes suffices to drive an IFN-I
response
Having defined downstream signaling components 
that relay IFNβ expression in human monocytes, 
we next addressed whether TLR2 internalization is 
required to initiate these signaling cascades. In 
LPS-stimulated macrophages, internalization of 
TLR4 molecules is a prerequisite for promoting 
IFN-I expression (29), which coincides with 
surface TLR4 downregulation. In contrast, TLR2 
surface levels on THP1 monocytes remained 
constant following P2C or P3C stimulation (data not 
shown). This implies that a majority of receptors 
stays at the plasma membrane after stimulation, but 
does not rule out the possibility that a small 
fraction of TLR2 molecules is internalized and 
responsible for initiating IFN-I signaling. 
In case of TLR4, one route of internalization is via 
macropinocytosis, a process depending on the co-
receptor CD14 (54). CD14 also acts as a co-
receptor for TLR2, in particular for capturing 
triacylated ligands (55) that are recognized by 
TLR2/1 heterodimers. As THP1 monocytes do not 
express CD14 (Supporting Fig. 1A), CD14-
dependent processes were not involved in the 
observed TLR2-induced IFNβ expression. When 
stably introduced into THP1 cells (Supporting Fig. 
5A), CD14 expression did not substantially 
increase P2C- or P3C-induced levels of IFNβ and 
ISG54 transcripts (Supporting Fig. 5B) or ISG15 
proteins (Supporting Fig. 5C,D). Thus, the absence 
of CD14 did not negatively impact TLR2-
dependent IFN-I responses in human monocytes, 
rendering receptor internalization via 
macropinocytosis an unlikely requirement.
Surface TLRs, including TLR2 and TLR4, can be 
internalized through clathrin-dependent 
endocytosis (54,56,57). To examine whether 
endocytosis is necessary for TLR2-induced IFN-I
signaling, THP1 monocytes were (pre)incubated 























concentration ranges that were not toxic, as they 
did not interfere with ISG15 induction by IFNα 
(Fig. 6A; Supporting Fig. 6). Chlorpromazine 
(CpZ) inhibits the formation of clathrin-coated pits 
at the cell surface, while chloroquine (CQ) and 
bafilomycin A1 (BafA) block endosome 
maturation by preventing endosomal acidification 
(58,59). CpZ, CQ, and BafA did not prevent 
upregulation of ISG15 in response to four well-
defined ligands for TLR1/2 and/or TLR2/6 
heterodimers (P2C, P3C, FSL-1, LTA; Fig. 6A; 
Supporting Fig. 6). In line with this, the 
endocytosis inhibitors did not significantly reduce 
P2C-induced IFNβ mRNA levels (Fig. 6B). This 
strongly suggests that TLR2 can induce IFN-I
signaling independently of receptor endocytosis 
and implies that the signaling events leading to 
IFN-I production either originate from the plasma 
membrane or from a pre-existing intracellular pool 
of receptors.
To specifically assess the outcome of TLR2 
signaling from the cell surface, we immobilized a 
biotin-conjugated derivative of P2C on 
streptavidin-coated culture wells to prevent cells 
from internalizing these ligands (Fig. 6C). In 
parallel, unconjugated P2C served as a negative 
control, as it cannot bind to streptavidin. After 
removal of unbound ligand through washing steps, 
THP1 Dual monocytes were incubated onto the 
coated wells and, after 24hrs, levels of NF-κB-
SEAP and IRF-Lucia reporter proteins were 
determined in the supernatants. Cells incubated in 
wells treated with unconjugated TLR2 ligand 
produced low levels of both reporter proteins, 
likely caused by minor, non-specific, adherence of 
the ligand to the wells (Fig. 6C, condition 1). 
Markedly higher levels of both NF-κB-SEAP and 
IRF-Lucia were detected in the culture 
supernatants of cells incubated on immobilized 
P2C-biotin (Fig. 6C, condition 3). Moreover, when 
we pre-blocked streptavidin-coated wells with D-
biotin to prevent immobilization of P2C-biotin on 
streptavidin, reporter induction triggered by P2C-
biotin was significantly reduced to levels 
comparable to those induced by remaining 
unconjugated P2C (Fig. 6C, condition 4 compared 
to 1 and 2). These combined findings show that the 
immobilized fraction of P2C-biotin induced both 
NF-κB and IRF activity in THP1 Dual monocytes, 
thereby demonstrating that TLR2 signaling from 
the cell surface of monocytes can initiate both a 
proinflammatory and an IFN-I response.
Discussion
In this study, we found that diverse TLR2 ligands 
evoke an IFN-I response in human monocyte-like 
cells, which is lost upon differentiation into 
macrophages. Stimulated monocytes transiently 
express modest levels of IFNβ resulting from a 
signaling cascade (Fig. 7) that 1) occurs upon 
exposure to TLR2/1 and TLR2/6 ligands, 2) 
critically depends on the signaling adaptor MyD88, 
3) involves TBK1 and IRF3 activity, 4) is 
complemented by robust TAK1/IKKβ-induced 
activation of NF-κB, rather than of AP-1, and 4) 
does not require TLR2 internalization. The levels
of IFNβ produced by TLR2-activated monocytes 
supported productive downstream IFN-I signaling. 
In contrast, the TLR2 response in macrophages 
was limited to NF-κB-dependent proinflammatory 
cytokine production. Thus, monocytes and 
macrophages employ distinct molecular 
mechanisms to regulate the quality of the innate 
response following human TLR2 engagement, in 
particular with respect to IFN-I induction.
Differentiation-dependent outcomes of TLR2 
signaling in human cells may well have contributed 
to the inconsistent findings in studies addressing 
whether the IFN-I response observed downstream 
of murine TLR2 could be extrapolated to human 
TLR2. Our findings are in line with, extend, and 
complement a very recent report by Musilova et 
al., who reported that primary human monocytes 
as well as undifferentiated THP1 cells secreted 
relatively low levels of IFN-I when they were 
cocultured with live S. aureus or LTA, which is an 
S. aureus-derived  TLR2 ligand (49). They did not 
study differentiated THP1 cells, for which we 
observed that the TLR2-induced IFN-I response 
was selectively lost (Fig. 1A,B, 2B-D; Supporting 
Fig. 2B); this was also the case for primary M1 and 
M2 macrophages (Supporting Fig. 7). Cumulative 
evidence now supports that human TLR2 signaling 
in monocytes can yield an IFN-I response in 
addition to the well-established proinflammatory 
























The molecular basis for why the monocyte IFN-I
response downstream of human TLR2 is 
selectively lost upon differentiation is unclear. 
Before and after PMA-differentiation, cells mount 
comparable TLR2-dependent proinflammatory 
responses (Fig 1A,B, 2B) and levels of TLRs and 
signaling adaptors are not reduced upon 
differentiation (Supporting Fig. 1). THP1 
macrophages have upregulated CD36 and CD14 
(Supporting Fig. 1), two co-receptors for TLR2/6 
and TLR2/1 heterodimers, respectively (55,60),
but elevated co-receptor expression has been 
associated with increased TLR2 signaling rather 
than reduced (61). We, therefore, conclude that the 
inability of human macrophages to mount an IFN-
I response via TLR2 is not due to loss of (co)-
receptor expression. Further research is warranted 
to decipher at what level signaling downstream of 
TLR2 diverges between monocytes and 
macrophages to culminate in distinct signaling 
outcomes. Additionally, it is as yet unclear what 
the biological meaning of this would be.
With respect to the differentiation-dependent 
signaling outcome, human TLR2 differs from 
mouse TLR2, as the latter yields IFN-I responses 
in both monocytes and macrophages (32,33). Yet, 
under the right conditions, IFN-I synthesis can be 
initiated by TLR2 ligands in myeloid cells from 
both species. Combined with the recent 
observation that TLR2-stimulated human pDCs 
produce IFNα (62), it demonstrates that the 
outcome of TLR2 signaling in some human cells 
includes not only a proinflammatory response, but 
also an additional IFN-I response.
One way to regulate TLR signaling outcome is by 
the use of alternative signaling adaptors. The 
prototypic switch downstream TLR4 from 
proinflammatory signaling to IFN-I is explained by 
displacement of TIRAP/MyD88 by TRAM/TRIF 
(28,63). Accordingly, while LPS-stimulated 
peritoneal macrophages lacking MyD88 no longer 
produced proinflammatory cytokines, 
TRAM/TRIF-dependent IFN-I signaling remained 
(64). Also human ΔMyD88 THP1 macrophages 
were still capable of producing IFNβ and ISGs 
following TLR4 stimulation (Fig. 3A,B, right 
panels, and D). In contrast, MyD88 was essential 
downstream TLR2 activation: IFN-I and ISG 
expression by human THP1 monocytes were 
ablated by knockout (Fig. 3A,B, left panels, 3C; 
Supporting Fig. 2C) or reduced by silencing (49)
of MyD88. From this, we conclude that TLR2 
activation on human monocytes does not appear to 
yield IFN-I output through displacement of 
MyD88 from the receptor by other adaptors. The 
ability to induce both proinflammatory and IFN-I
signaling through a single adaptor protein is not 
unique, since TLR7 and TLR9 also confer both of 
these responses through MyD88 in pDCs (65). In 
the mouse, several examples support MyD88-
dependency of IFN-I induction downstream of 
TLR2. Murine cytomegalovirus (MCMV) and VV 
triggered IFN-I via TLR2 in wild type, but not in 
ΔMyD88 inflammatory monocytes (32) and 
synthetic TLR2 ligands failed to induce 
proinflammatory cytokines (TNFα, IL12) and 
IFNβ in ΔMyD88 BMDMs (33). Without 
displacing MyD88, other adaptor molecules 
expressed by monocytes (Supporting Fig. 1) could 
still aid in the induction of IFN-I. Roles for TRAM 
and TRIF have been proposed in murine TLR2 
signaling (37,66), where TRAM appeared to 
interact with both TLR2 and MyD88 (37).
Although we did not investigate the contributions 
of TRAM and TRIF, silencing of these adaptor 
molecules did not have a major impact on human 
TLR2-induced IFN-I signaling (49). Based on 
these combined observations, MyD88 adaptor 
switching does not appear to be a mechanism by 
which human monocyte-like cells regulate IFN-I
production in response to TLR2 ligands.
While human TLR2 initiated both IFN-I and 
proinflammatory cytokines responses via MyD88, 
the minimal ligand dose for IFN-I induction might 
be higher than that for a proinflammatory response 
(Fig. 2A). The question then arises how higher 
ligand doses could affect the downstream signaling 
cascade. Therefore, we analyzed which signaling 
intermediates are involved in the IFN-I response. 
In general, IRFs are the transcription factors 
activated to induce IFN-I following TLR 
stimulation (67), while proinflammatory cytokines 
are instead produced from the NF-κB pathway. The 
IRF family comprises nine members, which are 
differentially expressed among cell types. IRF1, 
IRF3, IRF5, and IRF7 have been implicated in 
IFN-I transcription (52), with certain IRFs 























TLR activated. For instance, TLR4 strongly 
activates IRF3 in macrophages, through the TRIF-
dependent pathway (28) and IRF3-IFNβ promoter 
interactions are stabilized by the myeloid-specific 
transcription factor IRF8 (68). Downstream of 
TLR7 and TLR9 in pDCs, IRF7 mainly drives the 
IFN-I response (69). For TLR2 in murine cells, 
multiple IRF family members, including IRF1, 
IRF3, IRF7, and IRF8, have been implicated in 
regulating IFNβ expression (32,33,37,66,70), but 
their relative contributions remain unclear. In 
human cells, we now show that TLR2-dependent 
IFN-I signaling is virtually lost in IRF3 knockout 
THP1 monocytes (Fig. 4F,G), whereas NF-κB 
signaling is unaltered; this reveals the important 
role IRF3 plays in facilitating IFN-I synthesis. To 
a lesser extent, IRF7 and IRF8 also contribute 
(Supporting Fig. 3). The limited role of IRF7 is 
likely explained by the kinetics of TLR2-induced 
IFNβ transcription, which peaks at times when 
IRF7 levels are low (Fig. 1C). IRF8 could serve to 
enhance IRF3 effects, as described above for TLR4 
signaling. Of note, IRF8 may also act indirectly, as 
it regulates transcription of developmental genes in 
addition to specific ISGs (71). The major role we 
found for IRF3 in the induction of IFN-I
downstream of human TLR2 is reminiscent of that 
downstream of TLR4 (64). Unlike the latter, the 
indispensability of IRF3 for TLR2 was - to our 
surprise - not accompanied by common hallmarks 
of IRF3 activation, such as its phosphorylation 
(Fig. 4B) or nuclear translocation (data not shown). 
We hypothesize that this reflects limited IRF3 
activity, which would underlie the more modest 
IFN-I response in TLR2-stimulated monocytes 
compared to TLR4-stimulated macrophages (Fig. 
1A and 3C,D). 
How then is this limited IRF3 activity achieved? 
The non-canonical IKKs TBK1 and IKKε regulate 
IRF3 through phosphorylation (30). Robust 
activation of TBK1 occurred upon TLR2 ligation 
on the monocytes (Fig. 4B) and was essential for
the IFN-I response (Fig. 4C-E). Although efficient 
phosphorylation of IRF3 requires TBK1 to interact 
with adaptor proteins containing a conserved 
pLxIS motif, such as TRIF (72,73), in human 
monocytes, modest IFN-I levels were induced via 
TLR2 irrespective of TRIF expression (49). In 
vitro, TBK1 can - inefficiently - phosphorylate 
IRF3 in the absence of TRIF (74) and, therefore, 
this kinase might by itself impose low level 
phosphorylation onto IRF3 in TLR2-stimulated 
human monocytes ensuring a limited IFN-I
response. 
Having only low levels of IRF activity might not 
be sufficient to fully drive TLR2-dependent IFNβ
expression and appears to be complemented by 
NF-κB. Two kinases involved in the NF-κB 
signaling cascade, TAK1 and IKKβ, contributed to 
the TLR2-induced IFN-I response in human 
monocytes (Fig. 5); TAK1-induced events that 
trigger AP-1 activity did not appear to be involved 
(Supporting Fig. 4). Cross-talk between 
TBK1/IKKε and IKKβ has been reported (48),
suggesting that TBK1 activity may add to proper 
NF-κB activation downstream TAK1. A precedent 
of concerted actions of IRF3 and NF-κB in 
initiating IFN-I synthesis is provided by Newcastle 
Disease Virus (NDV)-infected cells (75). Late in 
infection, NDV evokes robust IRF3 activity and 
IFNβ expression, but during the first 6hrs, limited 
IRF3 activation is not sufficient for detection in a 
dimerization assay. It is at these early times that 
complementation by NF-κB signaling is crucial for 
modest IFNβ expression. Thus, NF-κB becomes 
particularly important for IFN-I synthesis when 
IRF activity is limited.
In summary (Fig. 7), combined activities of kinases 
like TBK1, IKKβ, and TAK1 culminate in 
activation of IRF3 and NF-κB to jointly effectuate 
a modest level of IFNβ transcription downstream 
TLR2 in human monocytes.
In addition to the use of distinct signaling adaptors 
and intermediates to regulate IFN-I, differential 
outcomes of TLR signaling could originate from 
distinct cellular locations. A striking observation 
we made is that, in human monocytes, the MyD88-
dependent signaling events driving IFNβ 
expression in response to the TLR2 ligand P2C did 
not require receptor internalization (Fig. 6A,B) and 
were induced from the cell surface (Fig. 6C). This 
contrasts with macrophages requiring TLR4 to be 
internalized through endocytosis in order to 
support TRIF-dependent signaling pathways 
towards IFN-I (28), yet is in line with continued
signaling via the MyD88 signaling adaptor (Fig. 3; 
Supporting Fig. 2C). Earlier studies yielded 























internalization as a requirement for inducing 
signaling events. Using microscopy, TLR2 fusion 
proteins as well as fluorescent TLR2 ligands have 
been observed at the plasma membrane and in 
endosomes (57,66,76). Increased internalization 
kinetics upon TLR2 stimulation suggested a role 
for endocytosis in TLR2 signal transduction 
(33,37,66), but did not prove from which location 
signaling towards IFN-I originated; internalization 
could also serve to end signaling via receptor 
degradation. To functionally address the impact of 
blocking receptor internalization, chemical 
inhibitors of endocytosis are widely used. In our 
experiments, we used dose ranges of 
chlorpromazine, chloroquine, and bafilomycin A1 
that did not interfere with IFNAR signaling and 
found that blocking endocytosis did not alter IFN-
I signaling in response to multiple TLR2 ligands, 
with no detectable differences related to the 
receptor heterodimers that can be bound (Fig. 6A; 
Supporting Fig. 6). Circumventing potential off-
target effects that chemical inhibitors have on 
overall cell functioning, we showed that when P2C
was restrained extracellularly, monocytes still 
mounted an IFN-I response (Fig. 6C), thereby 
conclusively demonstrating that IFN-I
transcription can result from TLR2 signaling 
events induced at the plasma membrane. While our 
results seem in contradiction with the reduced 
secretion of IFN-I from endocytosis inhibitor-
treated THP1 monocytes infected with S. aureus
(49), the use of entire pathogens might not be one-
on-one comparable with an isolated small synthetic 
TLR2 ligand, as even stimulation with the S. 
aureus-derived TLR2 ligand LTA yielded IFN-I
signaling in treated cells (Fig. 6). Our data do not 
exclude the possibility that TLR2 can signal to 
IFN-I from intracellular vesicles in addition to 
from the cell surface. Finally, by restricting the 
TLR2 ligand P2C to the cell surface, we did not 
separate the spatial dependencies of TLR2/1 and 
TLR2/6 heterodimers for signaling to IFN-I, 
although we did not find indications that the IFN-I
responsiveness of P3C (TLR2/1) or FSL-1/LTA 
(TLR2/6) differed from P2C in other assays (Fig. 2, 
3A,B, 4F,G, 6A; Supporting Fig. 2). In the future, 
chemical approaches to generate diverse TLR2 
ligands that function exclusively intracellularly, 
may provide definitive insight into the signals 
originating selectively from TLR2 in endosomes 
(25). Our observation that human TLR2 can induce 
IFN-I signaling from the cell surface of monocytes 
(Fig. 6) at least indicates that the outcome of TLR2 
signaling is not as strictly regulated through TLR 
trafficking events in these cells as seen for TLR4 
in macrophages.
Our combined results reveal that cells resembling 
two myeloid differentiation stages differentially 
respond to TLR2 ligands, with monocytes 
producing both proinflammatory cytokines and 
modest levels of IFN-I, whereas macrophages only 
induce a proinflammatory response. Intriguingly, 
also TLR4 responses differ in human macrophages 
versus monocytes. Compared to macrophages, 
monocytes induce much lower levels of IFNβ 
following LPS stimulation, which has been 
observed both for THP1 cells (our unpublished 
results) and primary cells (77,78). Thus, TLR2 and 
TLR4 ligands both induce relatively modest levels 
of IFNβ in human monocytes, whereas TLR4 
signaling in macrophages is tailored to induce 
higher levels of IFN-I. Aside from playing a key 
role in the innate defense against infections 
(8,9,79), IFN-I also pose the risk of inflammatory 
damage (80). Monocytes circulate in the blood and, 
therefore, the production of high levels of IFN-I
systemically might do more harm than good. Yet, 
low levels of IFN-I may be beneficial for effector 
functions such as the polarization of innate and 
adaptive immune cells (81). The localized 
detrimental effects of high TLR4-induced IFN-I
levels by macrophages in infected tissues may, 
instead, be outweighed by the beneficial effects of 
clearing an infection. The finding that TLR2 (and 
TLR4) signaling and outcome differ not only 
between cell types, but even between 
differentiation states, may therefore reflect the 
importance of tailoring IFN-I output depending on 
cellular context. Specific mechanisms acting to 
limit TLR-induced IFN-I production in monocytes 
may have been overlooked earlier, since 
monocytes and macrophages were often assumed 
to similarly transduce TLR-signals. Delineation of 
such mechanisms is essential for the development 
of preventive or therapeutic intervention strategies 

























The human monocytic cell line THP1 (ATCC, 
TIB-202) was maintained in RPMI 1640 medium 
supplemented with 10% heat-inactivated FCS, 100 
U/ml penicillin, and 100μg/ml streptomycin. Wild-
type, ΔMyD88, ΔIFNAR2, and ΔIRF3 THP1 Dual 
NF-κB/IRF reporter cells were obtained from 
Invivogen and were cultured according to the 
manufacturer’s instructions. Cells were maintained 
at 37°C and 5% CO2. To generate differentiated 
macrophages, THP1 cells were treated with 150nM 
phorbol myristate acetate (PMA, Sigma-Aldrich) 
for 24h and were left to rest for another 24h before 
use in experiments, as described previously (82).
Lentiviral transductions
For knock-down experiments, pLKO.1-Puro
lentiviral vectors from the Sigma-Aldrich Mission 
shRNA library were used, two targeting IRF7 
(TRCN0000014861, TRCN0000014858), two for 
IRF8 (TRCN0000020984, TRCN0000020985), a 
non-targeting control (SH002), and a control 
targeting β2m (SH008). To construct a lentiviral 
vector encoding hCD14, the coding sequence of 
hCD14 was excised from pUNO-CD14 
(Invivogen) and cloned under the control of the 
hybrid EF1α-HTLV promoter in the pSicoR 
backbone (Addgene #11579); the final construct 
pSicoR.EF1α-HTLV.hCD14 was sequence 
verified. Third generation replication-deficient 
SIN recombinant lentiviruses were generated by 
PEI transfection of 293T cells with pCMV-VSVG, 
pMDLg-RRE, and pRSV-REV and the above 
lentiviral vectors. THP1 Dual cells were 
transduced with the lentivirus-containing culture 
supernatants by spin infection (2000RPM, 33°C, 
90min) in the presence of 8μg/ml polybrene. To 
obtain pure cell populations, cells transduced with 
shRNA constructs were selected with puromycin 
(0.6μg/ml, Invivogen). Transduced CD14-
expressing cells were stained with anti-CD14-
PerCP (MφP9, BD Biosciences) and CD14+ cells 
were sorted as described under flow cytometry.
Ligand stimulations
The following reagents were used to stimulate 
THP1 cells: TLR2/6 ligand FSL-1 (Invivogen), 
purified LTA from S. aureus (Invivogen; TLR2/6 
ligand), TLR2/1 ligand Pam3CSK4 (Invivogen), 
TLR4 agonist LPS (from E. coli O55:B5; 
Invivogen), hIFNα-2a (PBL assay science), and 
hTNFα (Miltenyi Biotec). The TLR2 ligand 
Pam2CSK4 (P2C) and a biotin-conjugated 
derivative (P2C-biotin) were synthesized in house 
(see Supporting Fig. 8 for further details on the 
chemical synthesis). Compounds 1-3 (Supporting 
Fig. 8) were synthesized in house: compound 2 was 
synthesized using stick’s diazotransfer reagent and 
Fmoc-Lys-OH and compounds 1 (83) and 3
(84,85) were synthesized via literature procedures. 
Peptide resins were purchased from Rapp 
Polymere.
Inhibitor treatments
Inhibitors targeting TAK1 (Takinib, MedChem 
Express), TBK1/IKKε (MRT67307, Sigma), and 
IKKβ (BI605906, MedChem Express) were used. 
To assess the involvement of MAPK pathways in 
determining TLR2 signaling outcome, inhibitors 
for JNK (SP600125, Invivogen), MEK1/2 
(PD0325901, MedChem Express), and p38α 
(Losmapimod, kindly provided by Dr. J. Neefjes) 
were applied. Endocytosis was blocked at different 
stages using chlorpromazine (Sigma), chloroquine 
(kindly provided by Dr. A de Wilde), and 
Bafilomycin A1 (Sigma). Cells were pre-incubated 
with inhibitors for 45-60min and subsequent ligand 
stimulations were conducted in the presence of the 
inhibitors.
NF-κB and IRF reporter assays
THP1 Dual reporter cells, plated in 96-well flat 
bottom plates, were stimulated for 24hrs in a final 
volume of 200μl. Three wells with 90.000 cells 
were tested for each experimental condition 
(ligand; dose). Culture supernatants were collected 
and levels of the two secreted reporter proteins 
were determined: secreted embryonic alkaline 
phosphatase (SEAP) reflects NF-κB activation, 
whereas Lucia luciferase is produced upon IRF 
activation. Colorimetric enzyme assays to detect 
SEAP were performed using QUANTI-Blue 
reagent (Invivogen) according to the 
manufacturer’s instructions. The enzyme induced 
color change was detected by measuring the optical 
density at 655nm using a Bio-Rad iMark 
microplate reader. The levels of Lucia luciferase in 
the samples were determined with a 
bioluminescent assay using QUANTI-Luc reagent 























conversion was detected using a Victor X3 
multilabel plate reader (PerkinElmer).
Selective stimulation of cell surface TLR2
P2C-biotin was immobilized on Pierce Streptavidin 
Coated High Sensitivity 8-Well strips (Thermo 
Scientific) by incubating the ligand for 1hr at 4°C 
in PBS/2.5%BSA. Wells treated with 
unconjugated P2C served as a control for non-
specific binding to the wells. Wells pre-blocked 
with D-Biotin (250μM, 4°C, overnight) served as 
negative controls, to which P2C-biotin was no 
longer able to bind. Strips were washed 4 times 
with PBS/2.5%BSA/0.5%Tween20 and 2 times 
with PBS/2.5%BSA to remove unbound ligand. 
THP1 Dual reporter cells were seeded into the 
culture wells and, after 24hrs, culture supernatants 
were collected for NF-κB and IRF reporter assays. 
RNA extraction and quantitative real-time PCR 
analysis (qRT-PCR)
RNA was isolated from cells (300.000 cells/well; 
24-well plates) at the indicated time points after 
stimulation using the NucleoSpin RNA kit 
(Machery-Nagel) or with TRIzol reagent 
(Invitrogen) according to the manufacturer’s 
protocols. RNA was quantified by measuring the 
OD260 on a Nanodrop ND-1000 (Isogen Life 
Science). cDNA was generated from 300-1000ng
total RNA using anchored oligo-dT primers (AB-
1247, Thermo Scientific, or PM-305L, Jena 
Bioscience) and Superscript III Reverse 
Transcriptase (Invitrogen). For each cDNA 
sample, expression of genes of interest was 
measured by qRT-PCR in triplicate, except for the 
data in Fig. 1C and Supporting Fig. 5B which were 
measured in duplicate, using iQ SYBR Green 
Supermix (Bio-Rad) on a CFx connect 
thermocycler (Bio-Rad). The primers used for 
qRT-PCR amplification are listed in Table 1. 
Relative expression (RE) levels were calculated 
using the ΔΔCt method (86), using GAPDH or β-
actin (ACTB) expression levels as an internal 
reference. Where indicated, fold mRNA inductions 
were calculated by normalizing the RE levels to 
that of the unstimulated control cells. 
Flow cytometry
To assess the surface display of indicated 
molecules, cells were treated with TruStain FcX 
(Biolegend) to block Fc-receptors in all 
experiments, except for Supporting Fig. 5A, and 
subsequently stained with antibodies diluted in 
PBS supplemented with 0.5% BSA and 0.02% 
sodium azide. The following antibodies were used: 
anti-CD11b-PE (ICRF44, BD Biosciences), anti-
TLR2-PE (TL2.1, eBioscience), anti-TLR4-A488 
(HTA125, eBioscience), anti-CD36-PE (5-271, 
Biolegend), anti-CD14-PE or anti-CD14-PerCP 
(both MφP9, BD Biosciences). 
ISG15 levels were determined using anti-hISG15-
PE (R&D Systems) on cells fixed with 2% PFA 
and permeabilized in saponin buffer (PBS, 2% 
FCS, 0.5% saponin). 
Samples were subjected to flow cytometry by 
measuring 10.000 cells per sample on an LSR II 
(BD Biosciences) and data were analyzed using 
FlowJo software (V10, Treestar). Data were gated 
for live cells using FSC/SSC. For Supporting Fig. 
1B, autofluorescence corrected GeoMFI values 
were used to calculate relative surface levels as 
indicated in the figure legend. Quantification of 
percentages ISG15-positive cells was based on 
gating as shown in Fig. 1D.
For cell sorting on an Aria III (BD Biosciences), 
cells were stained with antibodies diluted in sterile 
0.2μm filtered PBS containing 0.5% BSA.
Western blot analysis
Total cell lysates were generated in Pierce RIPA 
buffer (ThermoFisher), supplemented with 
cOmplete mini protease inhibitor (Roche), and 50 
U/ml benzonase (Santa Cruz). For the detection of 
phospho-proteins, 10mM of the phosphatase 
inhibitor NaF was added. Samples were subjected 
to 30min rotation at 4°C and centrifuged to remove 
cellular debris (13.000 rpm., 4°C, 5min). Lysates 
were denatured by adding Laemmli sample buffer 
containing 20mM DTT and heating for 5min at 
95°C. Precision Plus All Blue prestained protein 
standard (Bio-Rad) was used as a molecular weight 
marker. Proteins were separated on 10% SDS-
PAGE gels and transferred onto 0.2 μm 
nitrocellulose membranes using the Trans-Blot 
Turbo Transfer System (Bio-Rad). Membranes 























detection of phospho-proteins membranes were 
instead blocked using 5% BSA in TBS. Antibodies 
were diluted in immunobooster solution (TaKaRa) 
or 5% milk in TBS supplemented with 0.1% 
Tween20 (TBS-T). Blots were incubated overnight 
at 4°C with primary antibodies and for 30 to 45min 
at room temperature with secondary antibodies. 
Blots were washed with TBS-T. 
The following antibodies were used for staining: 
anti-IRF3 (Cell signaling, #11904), anti-IRF7 
(Santa Cruz, sc-74471), anti-IRF8 (Santa Cruz, sc-
365042), anti-RIG-I (Cell signaling, #3743), anti-
TBK1 (Cell signaling, #3504), anti-phospho-
TBK1 (Cell signaling, #5483), anti-phospho-IRF3 
(Cell signaling, #4947), anti-STAT1 (Santa Cruz, 
sc-464), and anti-phospho-STAT1 (Cell signaling, 
#9167), anti-vinculin (Sigma, V9131) and IRDye 
conjugated secondary antibodies anti-Rabbit-
800CW (LI-COR) and anti-Mouse-680RD (LI-
COR). 
Proteins were visualized using the Odyssey CLx 
Imaging System (LI-COR). Stripping of blots prior 
to re-probing was performed using NewBlot IR 
stripping buffer (LI-COR) according to the 
manufacturer’s instructions.
Statistical analysis
Statistical analyses were performed using 
GraphPad Prism software. For the comparison 
between two groups, data were analyzed using the 
unpaired Student’s t-test. For multiple 
comparisons, wherein samples were compared to a 
control sample, one-way analysis of variance with 
Dunnett’s multiple comparison was performed. 
Statistical significance is indicated as *, p < 0.05 
and **, p < 0.01.
Data availability
Data described in this manuscript are available
from the corresponding author (Maaike E. Ressing, 
Leiden University Medical Center, Leiden, The 
Netherlands, m.e.ressing@lumc.nl) upon 
reasonable request.
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genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as 























Table 1 – List of primers for quantitative real-time PCR

































































Figure 1. Human TLR2 activation triggers IFN-I and ISG production, only in undifferentiated THP1 
cells. (A-E) Undifferentiated (monocytes) or PMA-differentiated (macrophages) THP1 Dual cells were 
stimulated with the TLR2 ligand P2C (100nM), TLR4 ligand LPS (1μg/ml), TNFα (50ng/ml), or IFNα 
(1000U/ml) for 24hrs (A,D,E) or for the indicated times (B,C). (A) To simultaneously compare activation 
of the IRF and NF-κB pathways in monocytes and macrophages, levels of IRF-Lucia and NF-κB-SEAP 
reporter proteins were determined in culture supernatants. Data are presented as means ±SD from a 
representative of at least five independent experiments (one-way ANOVA with Dunnett’s multiple 























transcription levels of IFNβ and various ISGs (CXCL10, ISG15, ISG54, IRF7, Viperin) as well as NF-κB 
regulated genes (TNFα, IL8, CCL5) downstream of TLR2 activation, expression of the indicated gene 
products was assessed by qRT-PCR and normalized to GAPDH. (B) For comparison of monocytes and 
macrophages, data are presented as relative expression (RE) levels (means ±SD) from a representative of 
three independent experiments. (C) To depict the kinetics of the IFN-I response in monocytes, relative 
expression levels were normalized to the unstimulated control (-, t=0) and presented as fold mRNA 
inductions (means ±SEM). (D,E) To visualize the IFN-I response at the protein level, upregulation of total 
ISG15 protein levels in permeabilized wild-type and ΔIFNAR2 THP1 monocytes was measured by flow 
cytometry. (D) Results are presented as histograms depicting ISG15 fluorescence intensities from a 
representative of three independent experiments. (E) For easier comparison of the responses, % ISG15-
positive cells ±SD were quantified from the experiments, by gating as shown in (D) (unpaired Student’s t-
























Figure 2. Diverse TLR2 ligands dose-dependently induce IFN-I signaling in human monocytes. THP1 
Dual monocytes (A,B) and macrophages (B) were stimulated with the TLR2 ligand P2C, TLR2/1 ligand 
P3C, or TLR2/6 ligand FSL-1 for 24hrs. (A) Dose ranges of ligands were used to compare IRF and NF-κB 
reporter activation in monocytes. (B) Stimulations of monocytes and macrophages were compared at ligand 
concentrations of 100nM P2C, 1μM P3C, 100nM FSL-1, or 1000U/ml IFNα. Reporter data are presented as 
means ±SD from a representative of five (A) or three (B) independent experiments (one-way ANOVA with 
Dunnett’s multiple comparison test). (C-D) ISG15 levels of monocytes versus macrophages were assessed 
after stimulation with P2C (1, 10, or 100nM), P3C (10, 100, or 1000nM), or IFNα (1000U/ml) for 24hrs. 
Results are shown as representative fluorescence intensity histograms of cells stimulated at the highest dose 
(C) and as % ISG15-positive cells ±SD (D) from three independent experiments (unpaired Student’s t-test). 
























Figure 3. Downstream human TLR2, MyD88 is indispensable for inducing IFN-I. Wild-type or
MyD88-knockout (ΔMyD88) THP1 monocytes or macrophages were stimulated with the TLR2 ligand P2C
(100nM), TLR2/1 ligand P3C (1μM), TLR4 ligand LPS (0.01, 0.1, or 1μg/ml), or IFNα (1000U/ml). (A,B)
ISG15 levels after 24hrs of stimulation were measured. Results are depicted as representative fluorescence 
intensity histograms of cells stimulated at the highest dose (A) and as % ISG15-positive cells ±SD (B) from 
three independent experiments (unpaired Student’s t-test). NS, not significant; **, p<0.01. (C,D) At the 
indicated time points after stimulation, relative expression (RE) of IFNβ and ISG54 transcripts was 
determined by qRT-PCR and normalized to GAPDH. For monocytes stimulated with P2C (C), data are 
presented as means ±SD from a representative of three independent experiments; for macrophages exposed 
























Figure 4. Human TLR2 triggers IFN-I via both TBK1 and IRF3. (A) Schematic overview of the IFN-I
signaling cascade investigated, with the level at which the inhibitor used (in C-E) acts. (B) Phosphorylation 
of TBK1, IRF3, and STAT1 was analyzed over time on total cell lysates of 100nM P2C-treated THP1 
monocytes (left) or 1μg/ml LPS-treated macrophages (right) by Western blot; vinculin served as a loading 
control. Out of four independent experiments, representative Western blots of the monocyte TLR2 
responses are shown; in this experiment, the control macrophage TLR4 response was included for 
comparison. (C-E) To determine the role of TBK1/IKKε kinase activity in TLR2 signaling outcome, 
monocytes were (pre)treated with the inhibitor MRT67307 (2.5μM in C,D; dose range 1.2-2.5-5μM in E). 
(C) At 1hr (IFNβ) and 4hrs (ISG54 and IL8) after stimulation with P2C (100nM), relative expression (RE) 
of the indicated transcripts was assessed by qRT-PCR and normalized to GAPDH. Data are presented as 
means ±SD from a representative of three independent experiments (unpaired Student’s t-test). (D,E)
Cellular ISG15 levels 24hrs after stimulation with P2C (100nM) or IFNα (1000U/ml) were measured. Data 
are depicted as fluorescence intensity histograms (D) and as % ISG15-positive cells ±SD (E) from three 
independent experiments (one-way ANOVA with Dunnett’s multiple comparison test). (F,G) To determine 























(100nM), TLR2/1 ligand P3C (1μM), TLR2/6 ligand FSL-1 (100nM), TNFα (50ng/ml), or IFNα 
(1000U/ml) for 24hrs. (F) Levels of IRF-Lucia and NF-κB-SEAP reporter proteins in culture supernatants 
are presented as means ±SD from a representative of four independent experiments (one-way ANOVA with 
Dunnett’s multiple comparison test). Fold inductions of the IRF-reporter are indicated above the bars. (G)
Percentages ISG15-positive cells ±SD are shown from three independent experiments (unpaired Student’s 
























Figure 5. The drivers of NF-κB activation TAK1 and IKKβ contribute to IFN-I signaling downstream 
of human TLR2. (A) Schematic overview of TLR2-induced signaling events under study that trigger NF-
κB and AP-1 activation, highlighting the branching of pathways downstream of TAK1 and the level at 
which the inhibitors used (in B-G) act. To determine the role of TAK1 kinase activity in TLR2 signaling 
outcome, THP1 monocytes were (pre)treated with the inhibitor Takinib (10μM in B,D; dose range 1-5-
10μM in E); to determine the role of the downstream kinase IKKβ, THP1 monocytes were (pre)treated with 
the inhibitor BI605906 (12.5μM in C,F; dose range 3.1-6.2-12.5μM in G). (B,C) At 1hr (IFNβ) and 4hrs 
(ISG54 and IL8) after stimulation with P2C (100nM), relative expression (RE) of the indicated transcripts 
was assessed by qRT-PCR and normalized to GAPDH. Data are presented as means ±SD from a 
representative of three independent experiments (unpaired Student’s t-test). (D-G) Cellular ISG15 levels 
24hrs after stimulation with P2C (100nM) or IFNα (1000U/ml) were measured. Data are depicted as 
fluorescence intensity histograms (D,F) and as % ISG15-positive cells ±SD (E,G) of three independent 























   
Figure 6. TLR2 can drive IFN-I expression from the surface of human monocyte-like cells,
irrespective of receptor internalization. (A-B) To evaluate the role of endocytosis in TLR2 signaling 
outcome, THP1 monocytes were (pre)treated with the inhibitor of clathrin-mediated endocytosis 
chlorpromazine (CpZ; dose range 6.2-12.5μM (A); 25μM (B)) or the inhibitors of endosome maturation 
chloroquine (CQ; dose range 7.5-15-30μM (A); 15μM (B)) or Bafilomycin A1 (BafA; dose range 25-50-
100nM (A); 50nM (B)). (A) Cellular ISG15 levels 24hrs after stimulation with TLR2 ligand P2C (100nM),























measured. Data are shown as % ISG15-positive cells ±SD from three independent experiments (one-way 
ANOVA with Dunnett’s multiple comparison test). Representative fluorescence intensity histograms are 
presented in Supporting Fig. 6. (B) At 1hr after stimulation with P2C (100nM), relative expression (RE) of 
the IFNβ transcript was assessed by qRT-PCR and normalized to GAPDH. Data are presented as means 
±SD from a representative of four independent experiments (one-way ANOVA with Dunnett’s multiple 
comparison test). (C) To assess if surface TLR engagement was sufficient to induce an IFN-I response, 
P2C-biotin was immobilized on the surface of streptavidin (SA)-coated plates (condition 3). Unconjugated 
P2C was taken along as a negative control that does not bind SA (condition 1). Control SA plates were pre-
blocked with D-biotin to prevent immobilization of the biotinylated TLR2 ligand (conditions 2 and 4). After 
culturing THP1 Dual reporter cells in these plates for 24hrs, levels of the reporter proteins reflecting NF-
κB (SEAP) and IRF (Lucia) activation were determined in the culture supernatants. Data are presented as 
means ±SD from a representative of three independent experiments (unpaired Student’s t-test). NS, not 
























Figure 7. Model for the TLR2-induced signaling events leading to IFNβ transcription in human 
monocyte-like cells. Ligand binding induces TLR2 heterodimerization with either TLR1 or TLR6. 
Activated receptor dimers recruit the adaptor MyD88 to transduce downstream signaling events. This 
results in modest and transient IFNβ expression, relying on the kinase activities of TAK1, IKKβ, and 
TBK1/IKKε. Via TAK1 and an IKK complex containing IKKβ, NF-κB is robustly activated. TBK1/IKKε, 
instead, regulate the activity of IRFs. IRF3 was identified as the dominant IRF for driving IFNβ expression, 
which may be aided by IRF7 and IRF8. Due to cross-talk with the canonical IKK-complex, TBK1 may 
additionally be involved in modulating NF-κB activity to appropriate levels (striped line). Overall, TLR2-
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